Scholarlink

<p>Waldenström Macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma characterized by bone marrow infiltration and monoclonal IgM secretion. Data on its clinical features and outcomes among Indian patients remain limited. This retrospective observational study evaluated demographic, clinical, and laboratory characteristics, treatment response, and two-year overall survival (OS) and progression-free survival (PFS) in 36 newly diagnosed WM patients treated between October 2020 and September 2025 at a tertiary care center in Kolkata. All patients received six cycles of bendamustine and rituximab (BR) chemotherapy. Response was assessed per IWWM-6 criteria, toxicity graded by CTCAE v5.0, and statistical analysis performed using SPSS 20.0 with <i>p</i> &lt; 0.05 considered significant. The mean age at diagnosis was 56.8 ± 12.4 years, with a male predominance (69.4%). Stage 3 (High-risk) disease was observed in 52.8%. The overall response rate was 83.3%, while two-year OS and PFS were 83.4% (95% CI: 72.0–96.5%) and 77.9% (95% CI: 65.3–92.7%), respectively. Median OS and PFS were not reached after a median follow-up of 25 months. Non-responders had significantly lower hemoglobin and higher β2-microglobulin and IgM levels (<i>p</i> &lt; 0.05). On univariate analysis, advanced age, higher IgM levels, thrombocytopenia, hepatomegaly, hyperviscosity, and stage 3 (high risk) disease predicted inferior OS (<i>p</i> &lt; 0.05). Common toxicities were neutropenia (22.2%) and thrombocytopenia (11.1%), mostly Grade 2–3 and managed conservatively. BR chemotherapy offers high response rates, favourable survival, and manageable toxicity in Indian WM patients, supporting its role in resource-limited settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Waldenstrom Macroglobulinemia – Experience From a Tertiary Care Hospital in Eastern India

  • 期刊论文

  • 发表日期：

    2026年4月4日

查看全文
  • Kaustav Ghosh,
  • Tuphan Kanti Dolai,
  • Shipla Roy

摘要

Waldenström Macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma characterized by bone marrow infiltration and monoclonal IgM secretion. Data on its clinical features and outcomes among Indian patients remain limited. This retrospective observational study evaluated demographic, clinical, and laboratory characteristics, treatment response, and two-year overall survival (OS) and progression-free survival (PFS) in 36 newly diagnosed WM patients treated between October 2020 and September 2025 at a tertiary care center in Kolkata. All patients received six cycles of bendamustine and rituximab (BR) chemotherapy. Response was assessed per IWWM-6 criteria, toxicity graded by CTCAE v5.0, and statistical analysis performed using SPSS 20.0 with p < 0.05 considered significant. The mean age at diagnosis was 56.8 ± 12.4 years, with a male predominance (69.4%). Stage 3 (High-risk) disease was observed in 52.8%. The overall response rate was 83.3%, while two-year OS and PFS were 83.4% (95% CI: 72.0–96.5%) and 77.9% (95% CI: 65.3–92.7%), respectively. Median OS and PFS were not reached after a median follow-up of 25 months. Non-responders had significantly lower hemoglobin and higher β2-microglobulin and IgM levels (p < 0.05). On univariate analysis, advanced age, higher IgM levels, thrombocytopenia, hepatomegaly, hyperviscosity, and stage 3 (high risk) disease predicted inferior OS (p < 0.05). Common toxicities were neutropenia (22.2%) and thrombocytopenia (11.1%), mostly Grade 2–3 and managed conservatively. BR chemotherapy offers high response rates, favourable survival, and manageable toxicity in Indian WM patients, supporting its role in resource-limited settings.